TBPH
Theravance Biopharma Inc.
NASDAQ
| Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||
| Revenue | 107.5M | 64.4M | 57.4M | 51.3M | 55.3M | 71.9M | 73.4M | 60.4M | 15.4M | 48.6M | 42.1M | 11.7M | 226,000 | 130.1M |
| Cost of Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||||||||
| R&D Expenses | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| SG&A Expense | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total Op. Expenses | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Income | -3.6M | -46.9M | -56.0M | -92.0M | -257.8M | -297.6M | -251.9M | -238.8M | -260.1M | -180.5M | -181.9M | -232.5M | -156.3M | -9.6M |
| EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Below the Line | ||||||||||||||
| Interest Expense | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Pre-Tax Income | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Income Tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Income | 105.9M | -56.4M | -55.2M | 872.1M | -199.4M | -278.0M | -236.5M | -215.5M | -285.4M | -190.7M | -182.2M | -237.0M | -156.3M | -9.6M |
| Per Share | ||||||||||||||
| EPS (basic) | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (diluted) | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Shares | ||||||||||||||
| Basic Shares | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted Shares | 52M | 49M | 55M | 74M | 69M | 62M | 56M | 54M | 52M | 53M | 38M | 32M | 0M | — |